Who Is Buying Pfizer? Hedge Fund Activity in 2026

Pfizer, the pharmaceutical giant behind the COVID-19 vaccine blockbuster, has been navigating a turbulent post-pandemic era. At around $28.32 per share, PFE trades well below its pandemic highs as investors grapple with declining COVID revenues, pipeline uncertainty, and the massive Seagen acquisition integration. Yet the stock's depressed valuation and hefty dividend yield are creating a battleground — and hedge funds are firmly split.

With 19 active funds tracked, Pfizer generates one of the most divided institutional ownership profiles in our universe. The 13F data reveals a fascinating tug-of-war between bulls seeing deep value and bears still heading for the exits.

Pfizer Institutional Snapshot

With 7 sellers outnumbering 6 buyers, Pfizer is one of the few stocks in our coverage where the selling pressure exceeds buying at the institutional level. This bearish tilt deserves careful examination.

Who's Buying Pfizer?

Despite the selling pressure, several notable funds are building significant positions:

Vanguard holds $15.3 billion and increased, continuing to accumulate shares across its index and active strategies. State Street similarly holds $8.5 billion and increased. The two largest passive managers adding creates a meaningful floor under the stock.

Canyon Capital made the most aggressive move on the buy side, increasing its position to a massive $495.7 million. This is a substantial bet from the credit-focused fund and suggests Canyon sees significant upside — possibly viewing Pfizer's current valuation as distressed relative to its pipeline potential and cash flow generation.

Two Sigma increased to $58.6 million, indicating that quantitative models are finding favorable signals in PFE's price action and fundamentals at these depressed levels.

Whale Rock Capital increased its smaller position to $250.5K, a more exploratory allocation but directionally aligned with the buy thesis.

Who's Selling Pfizer?

The selling side is deeper and features some heavyweight names:

Fidelity decreased its position to $347.6 million — a notable trim from one of the world's largest asset managers. When Fidelity reduces, it often reflects fundamental analyst downgrades across their research platform.

Citadel trimmed to $153.1 million, suggesting the multi-strategy firm is finding less favorable risk-reward in the pharma name.

Baker Bros Advisors, a healthcare-specialist hedge fund, decreased to $136.6 million. Baker Bros' reduction is particularly significant because they are among the most informed healthcare investors in the world. When a sector specialist sells, it carries extra weight.

D.E. Shaw reduced to $96.7 million, and Millennium Management cut to $55.2 million. Two of the largest quantitative and multi-strategy funds both trimming sends a clear signal that their models see deteriorating dynamics.

Notable Moves

Two complete exits stand out in this filing period: Renaissance Technologies and Balyasny Asset Management both SOLD their entire Pfizer positions.

Renaissance's exit is particularly telling. The firm's systematic models identified enough negative signals to warrant a complete liquidation rather than a mere trim. Similarly, Balyasny — a multi-manager platform known for its rigorous risk management — decided that zero allocation to Pfizer was optimal.

On the flip side, Canyon Capital's massive increase to nearly $500 million is the most contrarian bullish signal. Canyon appears to be positioning for a turnaround thesis, betting that the market has overshot to the downside and that Pfizer's pipeline, Seagen synergies, and dividend yield create compelling risk-reward.

The stark contrast — two quant firms exiting completely while a value-oriented fund nearly doubles down — makes Pfizer one of the most contested institutional positions in our tracking universe.

It's also worth noting the scale of selling from healthcare-specialist Baker Bros at $136.6 million. When a fund whose entire identity is built on pharmaceutical and biotech analysis decides to reduce a position, it carries more informational weight than a generalist trim. Baker Bros' team has the deepest understanding of drug pipelines, FDA dynamics, and competitive landscapes — their reduction should be weighed accordingly.

What This Signals

The institutional consensus on Pfizer is cautiously bearish with contrarian pockets of optimism:

The weight of evidence tilts negative. Seven sellers versus six buyers, combined with Renaissance and Balyasny's complete exits, paints a picture of an institutional investor base that is gradually losing patience with Pfizer's turnaround story. Baker Bros' reduction — from a fund that lives and breathes healthcare — is perhaps the most concerning single data point.

But the contrarians are committed. Canyon Capital's nearly $500 million bet is not a tentative position — it's a high-conviction call that the market is wrong. Combined with Vanguard and State Street continuing to accumulate at scale, there are serious institutional buyers willing to own Pfizer at these levels.

Valuation is the battlefield. At $28.32, Pfizer trades at historically cheap multiples with a generous dividend yield. The question dividing institutions is whether this cheapness is warranted (declining revenues, pipeline risk, Seagen integration) or represents a classic value opportunity (cash flows still robust, dividend sustainable, pipeline optionality).

The Seagen acquisition is the wild card. Pfizer's $43 billion purchase of Seagen brought a powerful antibody-drug conjugate (ADC) platform into the portfolio. If Seagen's pipeline delivers — particularly in oncology — it could transform Pfizer's growth profile and vindicate Canyon Capital's massive bet. Conversely, integration challenges or clinical disappointments would validate the sellers' concerns.

The dividend yield attracts but doesn't guarantee. Pfizer's generous dividend yield at current prices is a powerful magnet for income investors and creates a natural floor under the stock. However, institutional sellers appear to be looking beyond the yield and focusing on total return potential — suggesting they see limited capital appreciation even with the dividend included.

Monitor the next filing cycle closely. With the institutional investor base this divided, the next quarterly 13F data will be critical. If buyers increase or new positions emerge, it would validate the contrarian thesis. If selling accelerates, Pfizer could face additional institutional headwinds.

For investors considering Pfizer, the institutional data suggests patience may be required. The smart money is more cautious than optimistic, but the size of the contrarian bets — particularly Canyon Capital's nearly $500 million position — means a catalyst-driven re-rating could emerge quickly if the pipeline delivers.

---

Track PFE institutional moves in real-time with Freenance Smart Money — we track 35 funds with $21.4T total AUM across 77,111 positions. See who's buying and selling at app.freenance.io/smart-money/ticker/PFE.

Related Articles

• Who Is Buying NVIDIA? Hedge Fund Activity in 2026
• Who Is Buying Apple? Hedge Fund Activity in 2026
• Who Is Buying Tesla? Hedge Fund Activity in 2026

FAQ

Why is institutional sentiment on Pfizer so split?

PFE sits at the intersection of a structural revenue cliff (post-COVID vaccine and Paxlovid normalization) and a major M&A bet (the $43B Seagen acquisition). Bulls underwrite the oncology pipeline and dividend; bears focus on the patent cliff and integration risk — which is why 13F flows show 6 buyers, 7 sellers and 6 holders almost evenly balanced.

What is the Seagen acquisition and why does it matter?

Seagen brought Pfizer a leading antibody-drug conjugate (ADC) platform and several commercial oncology assets. The bull thesis is that ADC revenue and pipeline readouts replace declining COVID franchises through the late 2020s; the bear thesis is that the $43B price tag and integration drag weigh on returns before that contribution shows up.

Why does Baker Bros' reduction carry extra weight?

Baker Bros is a healthcare and biotech specialist — drug pipelines, FDA dynamics and competitive landscapes are their core competency. When a sector-specialist fund trims a name like PFE, it tends to carry more informational weight than a generalist sale because it reflects deep diligence on the actual pipeline.

Is Pfizer's dividend sustainable at current levels?

The dividend yield is historically high because the share price has fallen, not because the payout itself was cut. Institutional holders typically model dividend sustainability against free cash flow ex-COVID and the cost of integrating Seagen — the current consensus is that the dividend is covered, but with less cushion than during the COVID windfall years.

How can I follow PFE hedge fund positioning over time?

Freenance Smart Money tracks 13F filings from major funds quarter over quarter, so you can see whether contrarians like Canyon Capital keep adding, whether Baker Bros stabilizes or reduces further, and whether the systematic funds re-enter. That side-by-side view is the most useful way to monitor whether the "split sentiment" is resolving in either direction.